Ipsen, a global specialty-driven pharmaceutical group, today announced sales for the first quarter of 2017.

 

 

In the first quarter of 2017, Consolidated Group sales grew 19.1% to €438.0 million driven by Specialty Care growth of 25.4%¹ including growth of 86.3%¹ from North America.

 

Commenting on the first quarter 2017 performance, David Meek, Chief Executive Officer of Ipsen said: “In the first quarter, Specialty Care continued to drive remarkable organic top-line growth for Ipsen, led by the outstanding performance of Somatuline^®, both in the United States and Europe, as well as a strong acceleration for Dysport^®. We continue to face headwinds in certain emerging markets for our Consumer Healthcare business.” David Meek continued, “After the successful closing of the Onivyde^® transaction, our largest acquisition to date, we are focused on the successful execution of the Onivyde^® and Cabometyx^® launches. These two important products strengthen our presence in Oncology and will contribute meaningfully to our top-line growth and profitability in the coming years.”

 

Ipsen confirms its financial targets for 2017, with Specialty Care sales growth year-on-year greater than +18.0%¹, Consumer Healthcare sales growth year-on-year greater than +4.0%¹ and Core Operating margin greater than 24% of net sales.

 

In addition, Ipsen announces the change in name of its Primary Care division to Consumer Healthcare. This reflects the evolution over the last two years of the promotional model from classical prescription-based to a combination of prescription and over-the-counter (OTx) in select countries with gastrointestinal portfolios. The transaction announced in February to acquire a portfolio of select consumer healthcare assets from Sanofi will strengthen the evolution of the Consumer Healthcare portfolio in France and Central Europe with the strategic intent to further develop the OTx model in most geographies.